English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Assessing response to treatment for pulmonary sarcoidosis can be difficult (1). As more expensive agents are being considered for treatment of sarcoidosis, it is important that studies employ adequate and clinically relevant endpoints. A World Association of Sarcoidosis and other Granulomatous disease (WASOG) task force report on clinical trial endpoints examined those parameters reported in clinical trials of pulmonary sarcoidosis (2). The panel noted that several single endpoints had been used. With therapy, changes in forced vital capacity (3, 4) and DLCO (3) have been reported. Chest imaging has also been shown to improve with therapy (4). Two sarcoidosis specific quality of life instruments have been developed: the King’s sarcoidosis questionnaire (KSQ) (5) and fatigue assessment scale (FAS) (6). In addition, some treatments have been shown to be steroid sparing (7). The task force recommended that a composite score be developed to capture the many facets of pulmonary sarcoidosis (2). To date, no reports utilize composite scores to assess treatment efficacy in pulmonary sarcoidosis. We recently reported a prospective study of repository corticotropin injection (RCI) for chronic pulmonary sarcoidosis (8). In that study, many of the features were prospectively collected and allowed for the development of a composite score – Sarcoidosis Treatment Score (STS). Sixteen patients were enrolled in a single blind, prospective study. They underwent physiological, imaging, patient reported quality of life questionnaires, and prednisone tapering evaluations. These included: forced vital capacity (FVC) and diffusion lung of carbon monoxide (DLCO) measurement, high resolution computer tomography (HRCT) scan, King’s sarcoidosis health questionnaire general health (KSQ-GH) (5), FAS, and prednisone dosage tapering at baseline and after 7 and 24 weeks of therapy. A composite score was developed (STS) using these parameters with scoring ranging from -6 to +6 points (Table 1). Absolute change of FVC and DLCO % predicted of both 5% and 10% were calculated. The composite score was then compared to the individual features of the composite score and to six minute walk distance (6MWD). There was better correlation between the components of composite score and an absolute change of 5% versus 10% for FVC and DLCO percent predicted (data not shown). Therefore, further analysis used absolute change of 5%. Response (R) was defined as scores of ≥ 3/6 points; Partial Response (PR) was defined as scores of 2/6 points or stable with corticosteroid reduction (i.e., a total score of +1 due to ≥50% reduction in corticosteroid dosage); and Non Response (NR) was defined as scores of ≤1/6 points without significant corticosteroid taper (stable or deterioration). A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS)

A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS).